-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| Anti-coronavirus broad-spectrum monoclonal antibodies can cope with existing mutant strains |
Science and Technology Daily, Beijing, August 19 (Reporter Lu Chengkuan) The reporter learned from the Institute of Microbiology, Chinese Academy of Sciences on the 19th that researchers from the Institute and other units have developed a blocking type that can target multiple coronavirus invasion receptors, ACE2.
The monoclonal antibody h11B11 can effectively prevent and treat the infection of host cells and model animals by the novel coronavirus and its mutant strains, and has shown good safety in non-human primates
.
At the same time, as an antagonist of the new coronavirus invading the host receptor, the antibody shows superior broad-spectrum and neutralizing activity, and can deal with various mutant strains currently popular
Chinese Academy of Sciences
Variant strains of new coronaviruses continue to appear and spread faster and faster
.
This has brought huge challenges to the prevention and control of the new coronavirus, and it is urgent to develop effective therapies that can deal with various variants of the virus
Fortunately, recently, Chinese scientists have successfully isolated a humanized genetically engineered monoclonal antibody h11B11, which is directed against ACE2, the human angiotensin converting enzyme 2 receptor
.
The so-called monoclonal antibody is an immunoglobulin molecule, which belongs to biological drugs
.
After the outbreak of the new crown pneumonia, the monoclonal neutralizing antibody targeting the virus surface protein has become a potential effective treatment for new crown pneumonia.
The research results have great clinical application value for the antibody therapy of the new coronavirus, especially against the current multiple mutant strains
.
After the neutralization evaluation of pseudoviruses and true viruses of a variety of coronaviruses, the antibody was confirmed to have good inhibitory activity against the new coronavirus and its mutant viruses
At the same time, the antibody is used in combination with the new crown therapeutic antibody CB6 developed by the Institute of Microbiology in the early stage, which can synergistically improve the neutralizing activity
.
The CB6 therapeutic antibody is an antibody that targets the RBD of the new coronavirus S protein.
Dr.
Focus on the new crown pneumonia epidemic
